Where Will CRISPR Therapeutics Be in 10 Years?
Investor enthusiasm can wax and wane -- sometimes dramatically. Consider CRISPR Therapeutics (NASDAQ: CRSP), which is trading for around $61 a share, down from its high of $220.20 on Jan. 15, 2021.
But there is hope yet. The company is on the cusp of having its first therapy approved by the Food and Drug Administration (FDA). That therapy, exa-cel, was developed by CRISPR and Vertex Pharmaceuticals as a one-time curative treatment for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD).
Ten years from now, if the company makes this leap from a clinical-stage biotech to a commercial one, it likely will be trading for as much as $300 a share. Here's why.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€438.25
1.320%
With 58 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 459 € shows a slightly positive potential of 4.73% compared to the current price of 438.25 € for Vertex Pharmaceuticals Inc..
